Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis
Review identifies potential contributing factors and informs future development considerations; no new safety concerns identified.· The pre-specified interim analysis included 174 of 321 enrolled participants at 15 months after the first study injection. · The primary efficacy analysis did not achieve statistical significance, and the pre-specified continuation criteria were not met. · The Company is closing DIAGNODE-3 for futility in accordance with the trial’s pre-specified decision framework. · No new safety concerns were identified in connection with the interim